Literature DB >> 33554955

Alpha-1 antitrypsin deficiency impairs lung antibacterial immunity in mice.

Lena Ostermann1, Regina Maus1, Jennifer Stolper1, Lisanne Schütte1, Konstantina Katsarou1, Srinu Tumpara2, Andreas Pich3, Christian Mueller4, Sabina Janciauskiene2,5, Tobias Welte2,5, Ulrich A Maus1,5.   

Abstract

Alpha-1 antitrypsin (AAT) is a major inhibitor of serine proteases in mammals. Therefore, its deficiency leads to protease-antiprotease imbalance and a risk for developing lung emphysema. Although therapy with human plasma-purified AAT attenuates AAT deficiency-related emphysema, its impact on lung antibacterial immunity is poorly defined. Here, we examined the effect of AAT therapy on lung protective immunity in AAT-deficient (KO) mice challenged with Streptococcus pneumoniae. AAT-KO mice were highly susceptible to S. pneumoniae, as determined by severe lobar pneumonia and early mortality. Mechanistically, we found that neutrophil-derived elastase (NE) degraded the opsonophagocytically important collectins, surfactant protein A (SP-A) and D (SP-D), which was accompanied by significantly impaired lung bacterial clearance in S. pneumoniae-infected AAT-KO mice. Treatment of S. pneumoniae-infected AAT-KO mice with human AAT protected SP-A and SP-D from NE-mediated degradation and corrected the pulmonary pathology observed in these mice. Likewise, treatment with Sivelestat, a specific inhibitor of NE, also protected collectins from degradation and significantly decreased bacterial loads in S. pneumoniae-infected AAT-KO mice. Our findings show that NE is responsible for the degradation of lung SP-A and SP-D in AAT-KO mice affecting lung protective immunity in AAT deficiency.

Entities:  

Keywords:  Bacterial infections; Neutrophils; Proteases; Pulmonology

Year:  2021        PMID: 33554955      PMCID: PMC7934856          DOI: 10.1172/jci.insight.140816

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  60 in total

Review 1.  The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung.

Authors:  Francis X McCormack; Jeffrey A Whitsett
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

2.  The mechanism of Z alpha 1-antitrypsin accumulation in the liver.

Authors:  D A Lomas; D L Evans; J T Finch; R W Carrell
Journal:  Nature       Date:  1992-06-18       Impact factor: 49.962

Review 3.  Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: effects on pulmonary epithelium.

Authors:  P S Hiemstra; S van Wetering; J Stolk
Journal:  Eur Respir J       Date:  1998-11       Impact factor: 16.671

4.  Cathepsin G and neutrophil elastase play critical and nonredundant roles in lung-protective immunity against Streptococcus pneumoniae in mice.

Authors:  Ines Hahn; Anna Klaus; Ann-Kathrin Janze; Kathrin Steinwede; Nadine Ding; Jennifer Bohling; Christina Brumshagen; Hélène Serrano; Francis Gauthier; James C Paton; Tobias Welte; Ulrich A Maus
Journal:  Infect Immun       Date:  2011-09-12       Impact factor: 3.441

5.  Synthesis of alpha 1-anti-trypsin by human monocytes.

Authors:  R van Furth; J A Kramps; M M Diesselhof-den Dulk
Journal:  Clin Exp Immunol       Date:  1983-03       Impact factor: 4.330

Review 6.  Expanding the clinical indications for α(1)-antitrypsin therapy.

Authors:  Eli C Lewis
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

7.  Mechanism of alpha-1 antitrypsin endocytosis by lung endothelium.

Authors:  Sadaf Sohrab; Daniela N Petrusca; Angelia D Lockett; Kelly S Schweitzer; Natalia I Rush; Yuan Gu; Krzysztof Kamocki; Jana Garrison; Irina Petrache
Journal:  FASEB J       Date:  2009-05-07       Impact factor: 5.191

8.  Linkage of neutrophil serine proteases and decreased surfactant protein-A (SP-A) levels in inflammatory lung disease.

Authors:  F Rubio; J Cooley; F J Accurso; E Remold-O'Donnell
Journal:  Thorax       Date:  2004-04       Impact factor: 9.139

9.  Bacterial load and inflammatory response in sputum of alpha-1 antitrypsin deficiency patients with COPD.

Authors:  Bruno Balbi; Claudia Sangiorgi; Isabella Gnemmi; Ilaria Ferrarotti; Davide Vallese; Elena Paracchini; Lorena Delle Donne; Luciano Corda; Paolo Baderna; Angelo Corsico; Mauro Carone; Paola Brun; Francesco Cappello; Fabio Lm Ricciardolo; Paolo Ruggeri; Sharon Mumby; Ian M Adcock; Gaetano Caramori; Antonino Di Stefano
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-08-21

10.  TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice.

Authors:  Kathrin Steinwede; Stefanie Henken; Jennifer Bohling; Regina Maus; Bianca Ueberberg; Christina Brumshagen; Erik L Brincks; Thomas S Griffith; Tobias Welte; Ulrich A Maus
Journal:  J Exp Med       Date:  2012-10-15       Impact factor: 14.307

View more
  4 in total

Review 1.  Recent advancements in understanding the genetic involvement of alpha-1 antitrypsin deficiency associated lung disease: a look at future precision medicine approaches.

Authors:  Auyon J Ghosh; Brian D Hobbs
Journal:  Expert Rev Respir Med       Date:  2022-01-13       Impact factor: 3.772

2.  α1-Antitrypsin attenuates acute rejection of orthotopic murine lung allografts.

Authors:  Ann-Kathrin Knöfel; Sabina Janciauskiene; Tomoyuki Nakagiri; Sabine Wrenger; Kokilavani Sivaraman; Fabio Ius; Tobias Goecke; Patrick Zardo; Veronika Grau; Tobias Welte; Axel Haverich
Journal:  Respir Res       Date:  2021-11-17

3.  The collectin SP-A and its trimeric recombinant fragment protect alveolar epithelial cells from the cytotoxic and proinflammatory effects of human cathelicidin in vitro.

Authors:  Lidia de Tapia; Belén García-Fojeda; Nina Kronqvist; Jan Johansson; Cristina Casals
Journal:  Front Immunol       Date:  2022-08-29       Impact factor: 8.786

4.  Loss of Serpina1 in Mice Leads to Altered Gene Expression in Inflammatory and Metabolic Pathways.

Authors:  Sri Harsha Meghadri; Beatriz Martinez-Delgado; Lena Ostermann; Gema Gomez-Mariano; Sara Perez-Luz; Srinu Tumpara; Sabine Wrenger; David S DeLuca; Ulrich A Maus; Tobias Welte; Sabina Janciauskiene
Journal:  Int J Mol Sci       Date:  2022-09-09       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.